EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 -- -- Phase 3 PREVAIL CVOT overall event rate tracking in line with observed rate in BROADWAY -- -- ...
Camden Property Trust shifts from development to share repurchases amid multifamily oversupply, selling assets and buying ...
Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...
A lowered consent threshold could see more en bloc tenders being launched. (Photo: Samuel Isaac Chua/EdgeProp Singapore).A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback